



Image

1626


**In the United States Patent and Trademark Office**

Appl. No.: 10/088,060 Confirmation No. 6734  
Applicant(s): Alonso-Alija, et al.  
Filed: 06/27/2002  
TC/A.U.: 1626  
Examiner: Saeed, K.  
  
Docket No.: LeA 33878  
Customer No.: 35969

**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: OCT 24 2003



Beatriz Alviz

**RESPONSE TO RESTRICTION REQUIREMENT**

**Commissioner for Patents**

**P.O. Box 1450**


**Alexandria, VA 22313-1450**

Sir:

This is in response to the Office Action dated 09/24/2003. In response to the restriction requirement, applicants elect the claims of restriction group I for further prosecution in this application.

Applicants note that the examiner has placed method of treatment claims 19-27 in his restriction group VIII, but believe that it would be appropriate to group method of treatment claims 23-27 within restriction group I, as claims 23-27 relate to use of the compounds of formula (I) according to claim 3, while in restriction group I claims 3-8 and 13 relate respectively to compounds of formula (I) according to claim 3 and to pharmaceutical compositions containing them. Accordingly, the examiner is requested to consider including claims 23-27 as part of restriction group I.

Respectfully submitted,



William F. Gray

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175

Reg. No. 31018

Phone: (203) 812-2712

Date: 24 Oct '83